PD-1 Clinical Trials

9 recruiting

PD-1 Trials at a Glance

36 actively recruiting trials for pd-1 are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 20 trials, with the heaviest enrollment activity in Guangzhou, Shanghai, and Chengdu. Lead sponsors running pd-1 studies include Sun Yat-sen University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, and Tianjin Medical University Second Hospital.

Browse pd-1 trials by phase

Treatments under study

About PD-1 Clinical Trials

Looking for clinical trials for PD-1? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PD-1 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PD-1 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 36 trials

Recruiting

Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors

CancerPD-1Thyroid
Icahn School of Medicine at Mount Sinai17 enrolled1 locationNCT04615988
Recruiting
Phase 2

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Head and Neck CancerRadiotherapyAnti-PD-1/CTLA-4 Antibody
Second Affiliated Hospital, School of Medicine, Zhejiang University27 enrolled1 locationNCT07447570
Recruiting
Phase 1Phase 2

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

Pancreatic CancerPD-1 InhibitorPD-L1+2 more
Zhejiang Provincial People's Hospital10 enrolled1 locationNCT07312422
Recruiting
Phase 2

Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)

ImmunotherapyAFP Gastric or Gastroesophageal Junction AdenocarcinomaPD-1/CTLA-4+1 more
Hebei Medical University Fourth Hospital39 enrolled1 locationNCT07289997
Recruiting
Phase 2

Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Upper Urinary Tract Urothelial CarcinomaKidney PreservationHER-2 ADC+1 more
RenJi Hospital20 enrolled1 locationNCT05912816
Recruiting

Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics

Ulcerative Colitis (UC)Crohn Disease (CD)Autism Spectrum Disorder+6 more
Chen QiYi4,000 enrolled1 locationNCT07261826
Recruiting
Phase 2

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

TislelizumabPD-1 InhibitorKidney-sparing+2 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07233252
Recruiting
Phase 2

Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC

Neoadjuvant TherapyPD-1 InhibitorUpper Tract Urothelial Carcinoma+1 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07126119
Recruiting
Phase 2

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

Neoadjuvant TherapyTislelizumabPD-1 Inhibitor+3 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07125547
Recruiting
Phase 1

Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

Gastrointestinal TumorsPersonalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy
Ruijin Hospital40 enrolled1 locationNCT07067385
Recruiting
Phase 2

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

ChemotherapyPD-1 InhibitorInduction Therapy+2 more
The First Affiliated Hospital of Xiamen University208 enrolled3 locationsNCT06811844
Recruiting
Phase 1

Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer

Colorectal Cancer (CRC)PD-1Tumor Infiltrating Lymphocytes
Ruijin Hospital29 enrolled1 locationNCT07035002
Recruiting

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC
Nanfang Hospital, Southern Medical University20 enrolled1 locationNCT06327178
Recruiting
Phase 1Phase 2

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Solid TumorsLeptomeningeal MetastasisCTLA4+2 more
Guangzhou Medical University34 enrolled2 locationsNCT06809530
Recruiting
Phase 2

Neoadjuvant Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer

Colorectal Cancer (CRC)PD-1 InhibitorNeoadjuvant Immunotherapy+2 more
Sun Yat-sen University105 enrolled1 locationNCT06903858
Recruiting

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

CancerImmunotherapyPD-1+2 more
Oxford Biodynamics Inc.2,000 enrolled3 locationsNCT06635954
Recruiting

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Hepatocellular CarcinomaPD-1 InhibitorLenvatinib+1 more
Sun Yat-sen University300 enrolled1 locationNCT06333561
Recruiting

HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC

PD-1Systemic TherapyLenvatinib+3 more
First Hospital of China Medical University84 enrolled1 locationNCT06632093
Recruiting
Phase 1Phase 2

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Rectal CancerRadiotherapyAnti-PD-1 Antibody+2 more
West China Hospital20 enrolled1 locationNCT04636008
Recruiting
Phase 2

Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer

Cervical CancerRadiotherapyNeoadjuvant Chemotherapy+1 more
Shanghai Jiao Tong University Affiliated Sixth People's Hospital36 enrolled1 locationNCT05554276